2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Blood Banking, Cell Expansion, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Supportive Care, Biological Therapies, Transfusion, Non-Biological Therapies, Devices, Women’s Health, Adverse Events, Biological Processes, Apoptosis, Hematopoiesis, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Animal Model
PAPER

2905 Single-cell analysis of CD34+ cells mobilized from individuals with SCD using motixafortide shows signatures of enhanced quiescence in HSCs relative to plerixafor

Adam Benjamin Cornwell, MS, MS, PhD, Caroline Way, MS2, Preeti Dabas, PhD3, Aditya Barve, PhD4, Terri Cain, MS5, Alexis Leonard, MD6, Akshay Sharma Jr, MBBS7, Shannon McKinney-Freeman, PhD8
1 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
2 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
3 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
4 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
5 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
6 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
7 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
8 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States

Introduction

Sickle cell disease (SCD) is an inherited hemoglobinopathy that stems from pathological hemoglobin polymerization in red blood cells. Allogeneic hematopoietic cell transplant and autologous gene therapy (GT) remain the only available cures. Collecting hematopoietic stem cells (HSCs) for autologous GT requires mobilization with CXCR4 antagonists plerixafor or, more recently, the long-acting motixafortide, followed by apheresis and ex-vivo genetic modification. As the field advances toward in-vivo gene editing, HSC mobilization may facilitate transient peripheral blood (PB) access for non-viral editing before re-homing to the bone marrow (BM) (Li et al 2024).

The quality of mobilized HSCs may be particularly important in SCD, where chronic inflammation and BM stress contribute to HSC dysfunction, such as premature senescence (Barve et al 2026).  Motixafortide mobilizes more primitive HSCs than plerixafor in healthy middle-aged donors (Crees et al 2023), but whether this extends to SCD remains unknown. Further, it is unknown whether repeated collection days alter the composition of mobilized HSCs.

To address these questions, we performed single-cell RNA-Sequencing (scRNA-Seq) of CD34+ cells collected from young individuals with SCD from mobilization with either plerixafor or motixafortide to define differences in HSC composition, transcriptional state, and molecular signatures between mobilization strategies.

Methods

Mobilized PB samples were obtained from 3 motixafortide- and 4 plerixafor-mobilized participants with HbSS undergoing HSC collection for autologous GT. Plerixafor-mobilized samples included successive collection days: cycle 1 day 1 (C1D1) n=4, C1D2 n=4, C1D3 n = 1, C2D1 n = 3, C2D2 n=2, and C2D3 n=1, with collection cycles about one month apart. Individuals had HbSS genotype and ages ranged 15–20 years at mobilization. CD34+ cells were isolated from mobilized PB by Ficoll gradient centrifugation followed by magnetic bead selection (MACS) and fixed immediately for scRNA-Seq using Parse Biosciences Evercode Fixation. Cells were barcoded and libraries were prepared with Parse Biosciences Evercode WT Mega v3, followed by sequencing to depth of ≥20,000 reads per cell on Ultima UG100.

Results

Cell-level annotation identified 147,145 HSCs, representing 35.4% of all cells analyzed. Inter-donor variability was high, but was not due to batch effects, as samples from the same participant clustered together across plerixafor mobilization cycles. Clustering after Harmony integration identified 20 clusters, including two HSC-enriched clusters biased toward plerixafor (CL9,14) and two toward motixafortide (CL15,18).

Within HSCs, more than 150 differently expressed coding genes were identified between mobilization agents. Motixafortide-mobilized HSCs demonstrated increased expression of HES1, IER2, PTCH2, ID1, ID3, and CCNE1, with reduced expression of the EGF pathway genes AREG and HBEGF, consistent with enrichment of a more primitive/quiescent HSC population. Among the primitive HSC signature genes previously reported by Crees et al, only IER2 was similarly enriched, possibly reflecting differences between donor populations due to age and disease.

Despite these transcriptional differences, overall frequencies of HSCs and early progenitors were similar between the mobilization agents. Within plerixafor-treated participants, HSC frequency showed a nonsignificant decline between collection days 1 and 2. However, differential expression analysis suggested that later collection days were associated with progressively more metabolically active and lineage-biased HSCs. Finally, neither mobilization strategy demonstrated enrichment of transcriptional signatures for common senescence pathways, suggesting that HSCs with transcriptional features of cellular senescence are not preferentially mobilized and may remain in the BM under typical mobilization conditions.

Conclusion

Motixafortide mobilizes a transcriptionally distinct HSC population enriched for primitive/quiescent gene expression programs compared with plerixafor in individuals with SCD. Consecutive days of plerixafor mobilization may shift HSCs toward more metabolically active and lineage-biased states, while neither mobilization strategy preferentially mobilized HSCs with transcriptional features of senescence. These findings provide new insight into the biology of HSC mobilization in SCD and may inform optimization of stem cell collection strategies for gene therapy.

Adam Benjamin Cornwell, MS, MS, PhD: No relevant conflicts of interest to declare.